Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
89 hedge funds and large institutions have $95.1M invested in Paratek Pharmaceuticals, Inc. in 2019 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 24 increasing their positions, 29 reducing their positions, and 15 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
5% less funds holding
Funds holding: 94 → 89 (-5)
17% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 29
20% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 15
28% less capital invested
Capital invested by funds: $133M → $95.1M (-$37.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.38M |
| 2 |
WIC
Water Island Capital
New York
|
+$2.12M |
| 3 |
AC
Armistice Capital
New York
|
+$1.68M |
| 4 |
BC
Bruce & Co
Chicago,
Illinois
|
+$1.27M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$610K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$6.01M |
| 2 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
-$2.52M |
| 3 |
Millennium Management
New York
|
-$1.12M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.04M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$894K |
PRTK Hedge Fund Activity: Q2 2019 in Review
89 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q2 2019, worth a combined $95.1M — down 28% from $133M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of PRTK and 12 opened new positions — a net loss of 3 holders — while 29 trimmed existing stakes and 24 added.
The largest buyer was Vanguard Group, adding an estimated $2.38M. The largest seller was Highland Capital Management (Texas), cutting an estimated $6.01M.
- 89 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q2 2019, down from 94 in Q1 2019.
- Funds reported $95.1M of Paratek Pharmaceuticals, Inc. stock for Q2 2019, down 28% quarter-over-quarter.
- 12 funds opened new Paratek Pharmaceuticals, Inc. positions in Q2 2019 and 15 closed out, a net change of -3 holders.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q2 2019 was Vanguard Group, an estimated $2.38M added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q2 2019 was Highland Capital Management (Texas), an estimated $6.01M sold.
Based on aggregated 13F filings for Q2 2019.